EGFR and neoplasm: Prolonged IL-10’s half-life and well-tolerated.Targeted EGFR-positive tumors.Improved tumor-specific cytotoxic activity of CD8+ T cells.Hindered DC-mediated apoptosis of CD8+ TILs.Overcame resistance to ICIs therapy.